Effect of conventional dose of simvastatin on plaque regression and vascular remodeling in the peristent reference segments of normocholesterolemic patients: A serial intravascular ultrasound assessment

Korean Circulation Journal

Volumn 37, Issue 10, 2007, Pages 483-488

  Young, Joon Hong ^a   Myung, Ho Jeong ^a   Ahn, Youngkeun ^a   Jae, Youn Moon ^a   Kye, Hun Kim ^a   Hyung, Wook Park ^a   Ju, Han Kim ^a   Jeong, Gwan Cho ^a   Jong, Chun Park ^a   Jung, Chaee Kang ^a  

^a Chonnam National University Medical School   (South Korea)

Author keywords

Atherosclerosis; Intravascular ultrasonography; Regression; Statins

Indexed keywords

C REACTIVE PROTEIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; SIMVASTATIN;

ADULT; ANGIOCARDIOGRAPHY; ARTERY DIAMETER; ARTICLE; ATHEROSCLEROTIC PLAQUE; CHOLESTEROL BLOOD LEVEL; CLINICAL ASSESSMENT; CONTROLLED STUDY; CORONARY STENT; DRUG EFFECT; DRUG MECHANISM; FEMALE; FOLLOW UP; HUMAN; INTRAVASCULAR ULTRASOUND; MALE; RESTENOSIS;

EID: 36749075698     PISSN: 17385520     EISSN: 17385555     Source Type: Journal    
DOI: 10.4070/kcj.2007.37.10.483     Document Type: Article

References (27)

1. Hoffmann R, Mintz GS, Popma JJ, et al. Chronic arterial responses to stent implantation: a serial intravascular ultrasound analysis of Palmaz-Schatz stents in native coronary arteries. J Am Coll Cardiol 1996;28:1134-9.
2. Hoffmann R, Mintz GS, Dussaillant GR, et al. Patterns and mechanisms of in-stent restenosis: a serial intravascular ultrasound study. Circulation 1996;94:1247-54.
3. Mudra H, Regar E, Klauss V, et al. Serial follow-up after optimized ultrasound-guided deployment of Palmaz-Schatz stents: in-stent neointimal proliferation without significant reference segment response. Circulation 1997;95:363-70.
4. Weissman NJ, Wilensky RL, Tanguay JF, et al. Extent and distribution of in-stent intimal hyperplasia and edge effect in a non-radiation stent population. Am J Cardiol 2001;88:248-52.
5. Jimenez-Quevedo P, Sabate M, Angiolillo DJ, et al. Vascular effects of sirolimus-eluting versus bare-metal stents in diabetic patients: three-dimensional ultrasound results of the Diabetes and Sirolimus-Eluting Stent (DIABETES) Trial. J Am Coll Cardiol 2006;47:2172-9.
6. Serruys PW, Degertekin M, Tanabe K, et al. Vascular responses at proximal and distal edges of paclitaxel-eluting stents: serial intravascular ultrasound analysis from the TAXUS II trial. Circulation 2004;109:627-33.
7. Honda Y, Grube E, de La Fuente LM, Yock PG, Stertzer SH, Fitzgerald PJ. Novel drug-delivery stent: intravascular ultrasound observations from the first human experience with the QP2-eluting polymer stent system. Circulation 2001;104:380-3.
8. Cannon CP, Braunwald E, McCabe CH, et al. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med 2004;350:1495-504.
9. Nissen SE, Tuzcu EM, Schoenhagen P, et al. Effect of intensive compared with moderate lipid-lowering therapy on progression of coronary atherosclerosis: a randomized controlled trial. JAMA 2004;291:1071-80.
10. Libby P, Aikawa M. Mechanisms of plaque stabilization with statins. Am J Cardiol 2003;91:4B-8B.
11. Corsini A, Raiteri M, Soma MR, Gabbiani G, Paoletti R. Simvastatin but not pravastatin has a direct inhibitory effect on rat and human myocyte proliferation. Clin Biochem 1992;25: 399-400.
12. Roberts WL, Moulton L, Law TC, et al. Evaluation of nine automated high-sensitivity C-reactive protein methods: implications for clinical and epidemiological applications: part 2. Clin Chem 2001;47:418-25.
13. Walter DH, Schachinger V, Elsner M, Dimmeler S, Zeiher AM. Platelet glycoprotein IIIa polymorphisms and risk of coronary stent thrombosis. Lancet 1997;350:1217-9.
14. Strandberg TE, Vanhanen H, Tikkanen MJ. Effect of statins on C-reactive protein inpatients with coronary artery disease. Lancet 1999;353:118-9.
15. Ridker PM, Rifai N, Pfeffer MA, et al. Inflammation, pravastatin, and the risk of coronary events after myocardial infarction inpatients with average cholesterol levels. Circulation 1998;98:839-44.
16. Park SY, Kwak JJ, Park SH. Dose dependent changes of lipid profiles, IL-6 and CRP in unstable angina patients after simvastatin therapy. Korean Circ J 2003;33:663-70.
17. Dupuis J, Tardif JC, Cernacek P, Theroux P. Cholesterol reduction rapidly improves endothelial function after acute coronary syndromes. Circulation 1999;99:3227-33.
18. Son JW, Koh KK.Effects of statins on endothelium: vasomotor eunction, inflammation, and hemostasis. Korean Circ J 1999;29:1016-31.
19. Lacoste L, Lam JY, Hung J, Letchacovski G, Solymoss CB, Waters D. Hyperlipidemia and coronary disease: correction of the increased thrombogenic potential with cholesterol reduction. Circulation 1995;92:3172-7.
20. The Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease. Lancet 1994;344:1383-9.
21. Sacks FM, Pfeffer MA, Moye LA, et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl J Med 1996;335:1001-9.
22. Hong YJ, Jeong MH, Lim JH, et al. The prognostic significance of statin therapy according to the level of C-reactive protein in acute myocardial infarction patients who underwent percutaneous coronary intervention. Korean Circ J 2003;33:891-900.
23. Nakagawa T, Kobayashi T, Awata N, et al. Randomized, controlled trial of secondary prevention of coronary sclerosis in normocholesterolemic patients using pravastatin: final 5-year angiographic follow-up of the Prevention of Coronary Sclerosis (PCS) study. Int J Cardiol 2004;97:107-14.
24. Tamura A, Mikuriya Y, Nasu M. Effect of pravastatin (10 mg/day) on progression of coronary atherosclerosis in patients with serum total cholesterol levels from 160 to 220 mg/dL and angiographically documented coronary artery disease. Am J Cardiol 1997;79:893-6.
25. Suzuki M, Saito M, Nagai T, Saeki H, Kazatani Y. Prevention of positive coronary artery remodeling with statin therapy in patients with coronary artery diseases. Angiology 2006;57:259-65.
26. Jensen LO, Thayssen P, Mintz GS, Carlier SG, Pedersen KE, Haghfelt T. Effect of simvastatin on coronary lesion site remodeling. Cardiology 2006;106:256-63.
27. Petronio AS, Amoroso G, Limbruno U, et al. Simvastatin does not inhibit intimal hyperplasia and restenosis but promotes plaque regression in normocholesterolemic patients undergoing coronary stenting: a randomized study with intravascular ultrasound. Am Heart J 2005;149:520-6.